Cadila Healthcare Ltd has received US Food Drug Administration (US FDA) approval to market Promethazine tablets 12.5 mg, 25 mg and 50 mg in the US.
Promethazine is an anti-emetic drug, used to treat allergic symptoms and reactions, to cause sedation, to assist in controlling postoperative pain and to control motion sickness.
The company plans to launch the drug in US this year. The US market for this drug is estimated at $116 million.
The group had recently received approval to market Ribavirin capsules in the US market through its US subsidiary Zydus Pharmaceuticals Inc, it added.